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Abstract
Introduction Basal-like carcinomas (BLCs) and human epidermal
growth factor receptor 2 overexpressing (HER2+) carcinomas are
the subgroups of breast cancers that have the most aggressive
clinical behaviour. In contrast to HER2+ carcinomas, no targeted
therapy is currently available for the treatment of patients with BLCs.
In order to discover potential therapeutic targets, we aimed to
discover deregulated signalling pathways in human BLCs.
Methods In this study, we focused on the oncogenic
phosphatidylinositol 3-kinase (PI3K) pathway in 13 BLCs, and
compared it with a control series of 11 hormonal receptor negative-
and grade III-matched HER2+ carcinomas. The two tumour
populations were first characterised by immunohistochemistry and
gene expression. The PI3K pathway was then investigated by gene
copy-number analysis, gene expression profiling and at a proteomic
level using reverse-phase protein array technology and tissue
microarray. The effects of the PI3K inhibition pathway on
proliferation and apoptosis was further analysed in three human
basal-like cell lines.
Results The PI3K pathway was found to be activated in BLCs and
up-regulated compared with HER2+ tumours as shown by a
significantly increased activation of the downstream targets Akt and
mTOR (mammalian target of rapamycin). BLCs expressed
significantly lower levels of the tumour suppressor PTEN and PTEN
levels were significantly negatively correlated with Akt activity within
that population. PTEN protein expression correlated significantly
with PTEN DNA copy number and more importantly, reduced PTEN
DNA copy numbers were observed specifically in BLCs. Similar to
human samples, basal-like cell lines exhibited an activation of PI3K/
Akt pathway and low/lack PTEN expression. Both PI3K and mTOR
inhibitors led to basal-like cell growth arrest. However, apoptosis
was specifically observed after PI3K inhibition.
Conclusions These data provide insight into the molecular
pathogenesis of BLCs and implicate the PTEN-dependent activated
Akt signalling pathway as a potential therapeutic target for the
management of patients with poor prognosis BLCs.
AFA: alcohol, formalin and acetic acid; BLC: basal-like breast carcinoma; BSA: bovine serum albumin; CK: cytokeratin; CN: DNA copy number; 
EGFR: epidermal growth factor receptor; ER: oestrogen receptor; HER2: human epidermal growth factor receptor 2; HER2+ carcinomas: HER2 
overexpressing carcinomas; HES: haematoxylin-eosin-safran; IC50: inhibition concentration 50%; mTOR: mammalian target of rapamycin; MTT: 3-
(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide; PBS: phosphate buffered saline; PI3K: phosphatidylinositol 3-kinase; PIK3CA: PI3K p110 
subunit alpha; PIP3: phosphatidylinositol-3,4,5-trisphosphate; PR: progesterone receptor; PTEN: phosphatase and tensin homolog deleted on chro-
mosome 10; RPPA: reverse phase protein array; SNP: single nucleotide polymorphism; TBS: tris buffer saline; TBST: TBS + 0.1% tween-20; TBST-
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Introduction
Gene expression profiling has enabled the identification of five
subgroups of breast cancer characterised by different clinical
outcomes and responses to therapy [1-10]. Among them,
basal-like carcinomas (BLC) and human epidermal growth fac-
tor receptor 2 overexpressing (HER2+) carcinomas are asso-
ciated with the worst prognosis [6,10,11]. BLCs are highly
proliferative, genetically unstable, poorly differentiated, often
grade III carcinomas [12,13] and preferentially metastase in
the brain and lungs [14]. They are identified by immunohisto-
chemistry as triple negative (lack of HER2 and oestrogen/pro-
gesterone receptor (ER/PR) expression) and positive for basal
cytokeratins (CK5/6 and/or CK14) and/or epidermal growth
factor receptor (EGFR) expression [8,15]. BLCs represent
about 15% of cases of breast cancer and appear to be preva-
lent in pre-menopausal African American woman (39%) [16].
Patients with BLCs are treated exclusively with conventional
therapy. Although they show high rates of objective initial
response, the majority of patients do not have a complete, pro-
longed response, and they have a poorer prognosis than those
within other breast tumour subgroups [12,13]. In contrast to
HER2+ carcinomas treated with targeted therapy such as
anti-HER2 [17], there is no available targeted therapy for
BLCs. However, in patients with triple-negative breast cancer,
some treatments are in preclinical trials, such as Dasatinib, a
Src tyrosine kinase inhibitor, Cetuximab or Bevacizumab,
which target EGFR and vascular endothelial growth factor,
respectively [18]. Little is known about the pathogenesis of
BLCs in spite of the recent genome and transcriptome micro-
array profiling [14,15,19,20]. Proteomics in tandem with
genomic/transcriptomic analysis is essential to clarify the
molecular pathology of BLCs and to discover druggable tar-
gets [21,22].
In order to identify such targets, we are exploring the phospho-
proteome of BLCs to highlight deregulated signalling path-
ways. In this report, we have investigated the oncogenic
phosphatidylinositol 3-kinase (PI3K) pathway in BLCs and
compared it with that of HER2+ carcinomas in which it is
known to be up-regulated [23-25]. Phosphatidylinositol-3,4,5-
trisphosphate (PIP3) is an important lipid second messenger
in tumourigenesis, in particular by activating Akt, which binds
to membrane-associated PIP3 through its plekstrin homology
domain, and other signalling molecules involved in a variety of
cellular events, such as survival, proliferation, cell motility and
invasion [26]. PI3K is activated downstream of extracellular
signals and phosphorylates phosphatidylinositol-4,5-bisphos-
phate to generate PIP3. The tumour suppressor PTEN (phos-
phatase and tensin homologue deleted on chromosome 10)
catalyses the opposite reaction, thereby reducing the pool of
PIP3, inhibiting growth and survival signals, and suppressing
tumour formation [27,28]. The PI3K signalling pathway is fre-
quently deregulated in human solid tumours including breast
cancers through Akt1 or PIK3CA (catalytic subunit of PI3K)
mutations, HER2 overexpression and PTEN loss or mutation
[24,25,29-34].
In this report, we demonstrate that the PI3K pathway is acti-
vated in BLCs. The PI3K pathway was up-regulated in BLCs
compared with HER2+ carcinomas as shown by a significant
increased activation of downstream targets such as Akt and
mTOR (mammalian target of rapamycin). We also describe the
molecular mechanism leading to this PI3K pathway activation,
which occurs through a low PTEN protein expression that was
found to be associated with genomic alterations at the PTEN
locus, specifically in BLCs. In addition, we observed that
basal-like cell lines exhibited an activation of Akt and a low/lack
of PTEN expression. The exposure of basal-like cell lines to
PI3K or mTOR inhibitors led to cell growth arrest. However,
apoptosis was detected when PI3K, but not mTOR, was inhib-
ited. Altogether, our data demonstrate a PTEN-dependent up-
regulated PI3K pathway in BLCs and suggest this pathway as
a therapeutic target for patients with poor prognosis BLCs.
Materials and methods
Immunohistochemistry
Twenty-four tumours were obtained from patients treated at
the Curie Institute (Biological Resource Centre, Paris, France).
Immunohistochemistry was performed as previously
described [35]. Tumours contained between 50% and 90%
tumour cells revealed by haematoxylin-eosin-safran (HES)
staining.
For phospho-Akt (S473) staining, tissue microarrays (TMA)
containing alcohol, formalin and acetic acid (AFA)-fixed paraf-
fin-embedded tissue were made. For each biopsy, three repre-
sentative tumour areas and one peritumoural tissue were
carefully selected from a HES-stained section of a donor
block. Using a specific arraying device (Manual Tissue Arrayer;
Beecher Instruments, Sun Prairie, WI, USA) core cylinders of
1 mm in diameter were punched from each of those four areas
and placed into recipient paraffin blocks. Sections of 3 μm
were cut, placed onto positively charged slides (capillary gap
microscope slides, Dako REAL, Dako, Trappes, France) and
dried at 58°C for one hour. Sections were deparaffinised in tol-
uene and hydrated in graded alcohol. Antigen retrieval was
performed in 10 mM sodium citrate (pH 6.10) for 20 minutes
at 95°C. Sections were then cooled for 20 minutes at room
temperature. Endogenous biotins were blocked by Biotin
blocking system (Dako, Trappes, France).
After washes in PBS-Tween buffer, endogenous peroxidase
activity was quenched with 3% hydrogen peroxide for 5 min-
utes then rinsed in distilled water. Each tissue section was
blocked with a solution of PBS (pH 7.4) containing 1% of BSA
and 1.4% of normal horse serum for 5 minutes, followed by an
overnight incubation at 4°C with primary antibody against
phospho-Akt (S473). After washes, slides were incubated
with rabbit biotinylated antibody (Jackson Immunoresearch,Available online http://breast-cancer-research.com/content/10/6/R101
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Interchim, Clichy, France) for 30 minutes. Immunostaining was
revealed using the Vectastain ABC peroxidase system (Vector
Laboratories, Abcys, Paris, France) using diaminobenzidine as
a chromogen. Slides were counter-stained with haematoxylin
before mounting. The reactions were carried out using an
automated stainer (LabVision, Thermo Scientific, Microm
France, Francheville, France) except for the primary antibody.
Omission of the primary antibody was used as a negative con-
trol. Immunohistochemistry conditions were first optimised
using cell pellets from cell lines known to be positive or nega-
tive for phospho-Akt staining.
Positive nuclear staining for ER and PR were recorded in
accordance with standardised guidelines, using 10% as the
cut-off for ER- and PR-positive cells. For HER2, only staining
of membranes was considered with a 30% cut-off as recom-
mended [36]. The cut-off for CK5/6, CK14 and EGFR positiv-
ity was 10% of stained cells (weak or strong) for the results
shown in Figure 1a.
EGFR (clone 31G7, 1:40 dilution, Zymed, Invitrogen, Cergy-
Pontoise, France), CK5/6 (clone D5/16B4, 1:50 dilution,
Dako, Trappes, France), CK14 (clone LL002, prediluted, Bio-
genex, San Ramon, CA, USA) and phospho-Akt (S473) (clone
736E11, 1:50 dilution, Cell Signaling Technology, Ozyme,
Saint Quentin en Yveline, France) antibodies were used.
Tumour lysis
Frozen tumours were incubated with a lysis buffer containing
50 mM Tris (pH 6.8), 2% sodium dodecyl sulfate (SDS), 5%
glycerol, 2 mM 1,4-dithio-DL-threitol (DTT), 2.5 mM ethylene-
diaminetetraacetic acid, 2.5 mM ethylene glycol tetraacetic
acid, 2 mM sodium orthovanadate, 10 mM sodium fluoride and
a cocktail of protease (Roche, Meylan, France) and phos-
phatase (Pierce, Perbio, Brebières, France) inhibitors. Homog-
enisation was obtained using a TissueLyser (Qiagen,
Courtaboeuf, France) with stainless steel beads 5 mm in diam-
eter (Qiagen, Courtaboeuf, France) for two to three minutes at
30 Hz. Lysates were boiled at 100°C for 10 minutes to inacti-
vate proteases and phosphatases. Protein concentration was
determined using the BCA Protein Assay Kit-Reducing Agent
Compatible (Pierce, Perbio, Brebières, France). Lysates were
then stored at -80°C.
Reverse phase protein array
We developed a robust reverse phase protein array (RPPA)
technology allowing the printing of very small quantities of pro-
tein (about 1 ng per spot) convenient for the analysis of mini-
mal quantities of biopsy material. This miniaturised dot-blot
technology is based on robotic printing of a large number of
different cell/tissue lysates onto nitrocellulose bound to histol-
ogy slides and the analysis of proteins of interest with highly
specific antibodies [37,38]. Five two-fold serial dilutions were
made from each lysate in 96-well plates (conical bottom, 50
μl/well) and spotted in triplicates onto nitrocellulose-coated
glass slides (FAST slides, Whatman, Schleicher & Schuell,
Maidstone, Kent, UK) by using a MicroGrid Compact arrayer
(BioRobotics, Dutscher Scientific Instrumentation, Brumath,
France) with SMP3XB pins (Tip diameter = 75 μm, volume-
spot = 1.2 nl; Telechem, Proteigene, Saint Marcel, France).
To avoid evaporation during spotting, the humidity was kept at
about 50% to 60% in the array chamber with a humidification
control unit. After printing, slides coated with two nitrocellu-
lose pads were incubated with avidin, biotin and peroxydase
blocking reagents (Dako, Trappes, France) before saturation
with TBS containing 0.1% Tween-20 and 5% BSA (TBST-
BSA). Each pad was then probed overnight at 4°C with pri-
mary antibodies (or without primary antibodies, for negative
controls) at the appropriate dilution in TBST-BSA. After
washes with TBST, arrays were probed with horseradish per-
oxidase secondary antibodies (Jackson ImmunoResearch Lab-
oratories, Interchim, Clichy, France) diluted in TBST-BSA for
one hour at room temperature. To amplify the signal, slides
were incubated with Bio-Rad Amplification Reagent (BAR
solution) supplied in the Western blot amplification module
(Bio-Rad, Marnes la Coquette, France) for 10 minutes at room
temperature. The arrays were washed with TBST containing
10% dimethyl sulfoxide (DMSO) for two minutes, then with
TBST. To detect the bound biotin, slides were probed with
Cy5-Streptavidin (Jackson ImmunoResearch Laboratories,
Interchim, Clichy, France) diluted in TBST-BSA for one hour at
room temperature. The processed slides were scanned using
a GenePix 4000B microarray scanner (Molecular Devices,
Saint Grégoire, France). Double staining was performed to
quantify actin expression for the normalisation between sam-
ples using anti-beta-actin primary antibodies (Sigma-Aldrich,
Saint Quentin Fallavier, France) and Cy3 secondary antibod-
ies (Jackson ImmunoResearch Laboratories, Interchim, Clichy,
France).
Specificity of each primary antibody used in this study was first
validated by Western blotting on several cell and tumour
lysates (not shown). Optimal dilution was determined for each
antibody with different cell lysates using specific software
developed at the Curie Institute with the following criteria: sig-
nal away from the negative control without saturation and cor-
relation with Western blotting. Spot detection and
quantification were determined with MicroVigene software
(VigeneTech Inc, Carlisle, MA). Akt phospho-Akt (S473),
PTEN and stathmin antibodies (Cell Signaling Technology,
Ozyme, Saint Quentin en Yveline, France) were utilised at a
dilution of 1:1000, 1:250, 1:200 and 1:100, respectively.
HER2 antibodies (clone MS-432-P1, Ab11) used at 1:500
dilution were from Lab Vision (Interchim, Clichy, France).
mTOR expression and phosphorylation was not examined by
RPPA due to the poor specificity of mTOR antibodies.Breast Cancer Research    Vol 10 No 6    Marty et al.
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Western-blotting
Tissue lysates (10 μg/lane) were loaded onto 10% or four
12% Bis-Tris Criterion XT gels (Bio-Rad, Marnes la Coquette,
France) and migration was performed using MOPS buffer
(Bio-Rad, Marnes la Coquette, France). Proteins were then
transferred to nitrocellulose (Bio-Rad, Marnes la Coquette,
France). Membranes were saturated with TBST-BSA and then
incubated overnight at 4°C with primary antibodies at the
appropriate dilution in TBST-BSA. After washes, membranes
were incubated with horseradish peroxidase secondary anti-
bodies (Jackson ImmunoResearch Laboratories, Interchim,
Clichy, France) for one hour at room temperature. Bound anti-
bodies on immunoblots were visualised on membranes with a
chemoluminescent detection system (ECL; Amersham Phar-
macia Biotech, Orsay, France). Quantification was performed
using a LAS-3000 Luminescent Image analyser and Image
Gauge software (Fuji, FSVT, Courbevoie, France). Actin was
detected for normalisation between samples using anti-beta-
actin primary antibodies at the dilution of 1:5000 (Sigma-
Aldrich, Saint Quentin Fallavier, France). Akt, phospho-Akt
Figure 1
Characterisation of basal-like carcinomas (BLCs) and human epidermal growth factor receptor overexpressing (HER2+) carcinomas from human  biopsies Characterisation of basal-like carcinomas (BLCs) and human epidermal growth factor receptor overexpressing (HER2+) carcinomas from 
human biopsies. (a) Selection and characterisation of human samples by immunohistochemistry (IHC). Thirteen BLCs were first selected as grade 
III triple-negative ductal carcinomas (negative for oestrogen receptor (ER), progesterone receptor (PR) and HER2 expression) and then character-
ised for cytokeratin 5/6 (CK5/6), CK14 and epidermal growth factor receptor (EGFR) staining. The control series was composed of 11 hormone 
receptor negative- and grade III-matched HER2+ carcinomas. Tumours contained between 50% and 90% tumour cells revealed by haematoxylin-
eosin-safran staining. (b) Higher HER2 protein expression in HER2+ carcinomas compared with BLCs. The box plot illustrates the expression of 
total HER2 protein expression measured by reverse phase protein array (RPPA) in human BLCs and HER2+ carcinomas. An outlier is present within 
the HER2+ population (open circle). The y axis represents logarithmic transformed HER2 relative quantification. The p value (*** p < 0.001) is repre-
sented (Mann-Whitney test). Data are representative of three separate RPPA experiments. (c) Tumours selected by immunohistochemistry clustered 
according to their gene expression signature. A hierarchical clustering was performed on the intrinsic/UNC genes as described [46]. (i) Overview of 
complete cluster diagram. Each row represents a gene and each column a human tumour. Black is for no change, red for up-regulation and green for 
down-regulation of gene expression. (ii) Experimental sample-associated dendrogram. Red dendrogram branch represents HER2+ carcinomas and 
blue designs basal-like carcinomas. (iii) HER2+ signature. A HER2+ expression cluster was observed and contained multiples genes from the 
17q11 amplicon including HER2 and growth factor receptor-bound protein 7 (GRB7) (typed in red) as previously described [46]. (iv) Basal-like sig-
nature. A basal-like expression cluster was found and contained genes previously identified to be characteristic of basal epithelial cells such as v-kit, 
FOXC1 and P-cadherin (written in red) [46].Available online http://breast-cancer-research.com/content/10/6/R101
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(S473), mTOR, phospho-mTOR (S2448), PTEN and cleaved-
PARP antibodies (Cell Signaling Technology, Ozyme, Saint
Quentin en Yveline, France) were used at 1:1000 dilution.
HER2 antibodies (clone MS-432-P1, Ab11) were used at a
1:500 dilution (Lab Vision, Interchim, Clichy, France).
DNA and RNA microarray analysis
DNA and RNA were purified as described [20]. For genomic
arrays, Affymetrix GeneChip Human Mapping 100 K was nor-
malised and analysed using ITALICS (ITerative and Alternative
normaLIzation and Copy number calling for affymetrix Snp
arrays) algorithm [39]. The segmentation of the genomic pro-
file was performed using GLAD (Gain and Loss Analysis of
DNA) software [40]. The forceGL parameter was set to 0.28.
Single nucleotide polymorphisms with smoothing value lower
and greater than 2 ± 0.28 were considered as loss and gain,
respectively. After RNA quality control, 12 of the 13 BLCs and
the 11 HER2+ carcinomas were hybridised onto U133 plus
2.0 Affymetrix chips. Transcriptomic data were normalised
using GC-RMA [41]. Raw and normalised transcriptomic data
are publically available at Gene Expression Omnibus (Acces-
sion number: [GSE13787]) and at the Curie Institute microar-
ray dataset repositories [42].
Cell culture
The cell lines were obtained from the American Type Culture
Collection (LGC Promochem, Molsheim, France) and from the
European Collection of Animal Cell Cultures (Sigma-Aldrich,
Saint Quentin Fallavier, France). HCC38 and HCC1937 were
maintained in RPMI-1640 with 10% FBS, 1.5 g/L sodium
bicarbonate, 10 mM Hepes and 1 mM sodium pyruvate. BT20
were cultured in Eagle's minimal essential medium containing
10% FBS, 1.5 g/L sodium bicarbonate, 0.1 mM non-essential
amino acids and 1 mM sodium pyruvate. MDA-MB-468 were
grown with RPMI with 10% FBS. MDA-MB-453 were cultured
without carbon dioxide in Leibovitz's L-15 medium containing
10% FBS and 10 mM HEPES. SKBr3 were grown with
McCoy5a containing 10% FBS and A431 with Eagle's mini-
mal essential medium containing 10% FBS and 0.1 mM non-
essential amino acids. A431 cells were either or not stimulated
with 50 ng/ml EGF for five minutes after overnight serum star-
vation. Lysates were prepared at 60% to 90% cell confluency
and analysed by Western blotting.
Cell proliferation assay
To test the effect of LY294002 and rapamycin on cell prolifer-
ation, cells were seeded into 96-well plates at a density deter-
mined on the basis of the growth characteristics of each cell
line (750 cells/well for MDA-MB-468 and HCC1937; 1500
cells/well for BT20). Forty-eight hours later, cells (triplicate
wells) were treated for seven days with varying concentration
of LY294002 (Sigma-Aldrich, Saint Quentin Fallavier, France),
rapamycin (Cell Signaling Technology, Ozyme, Saint Quentin
en Yveline, France) or DMSO (Sigma-Aldrich, Saint Quentin
Fallavier, France) as a control. LY094002 concentrations
tested were 0.39, 0.78, 1.56, 3.12, 6.25, 12.5, 25 and 50 μM.
Rapamycin concentrations analysed were 0.49, 0.98, 1.95,
3.91, 7.81, 15.62, 31.25, 62.5, 125 and 250 nM.
The relative percentages of metabolically active cells com-
pared with untreated controls were determined on the basis of
mitochondrial conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide (MTT) to formazine using a MTT
assay. To each well, 15 μL of MTT (5 mg/mL in PBS) was
added. After four hours incubation at 37°C, floating plus
adherent cells were lysed by the addition of 10% SDS in 10
mM hydrochloric acid. The absorbance was measured at the
wavelength of 540 nm (Infinite 200, Tecan, Lyon, France) and
results are presented as the percentage of control cell growth
inhibition obtained from no treated cells grown in the same cul-
ture plate. The IC50s were determined on the basis of the
dose-response curves.
Apoptosis assays
Cells were harvested and seeded in 96-well plates (10 000
cells/well). After overnight growth, cells were treated in tripli-
cate with various concentrations of LY294002, rapamycin or
DMSO as a control. Twenty-four hours later, apoptosis was
determined by caspase 3/7 activation and by the detection of
PARP cleavage that serves as a marker of cells undergoing
apoptosis. Caspase activity was determined using Caspase-
Glo 3/7 luminescent assay (Promega, Charbonnières-les-
bains, France) according to the manufacturer's instructions.
Results are presented as caspase 3/7 activity normalised by
caspase 3/7 activity from vehicle-treated cells. For PARP
cleavage, Western blot was performed using whole protein
lysates of floating plus adherent cells. Blots were incubated
with a specific cleaved-PARP antibody (Cell Signaling Tech-
nology, Saint Quentin en Yveline, France).
Statistical analysis
As data did not display a normal distribution, a non-parametric
test was performed. Mann-Whitney test was used to assess
differential expression of a protein between the two groups
(BLCs and HER2+). The R software v2.4.0 was used for sta-
tistical analyses [43]. A Spearman correlation test was per-
formed to estimate a rank-based measure of association
between two parameters. Values were log transformed. p val-
ues under 5% were considered significant. For the apoptosis
assays, p values were calculated using Student's t test.
Results and discussion
Tumour selection and characterisation
The PI3K pathway was examined in two populations of highly
proliferative, grade III, hormone receptor-negative invasive
breast carcinomas. We chose this comparison, rather than
that of BLCs with normal tissue, to compare two types of pro-
liferating cells, avoiding a comparison with a largely differenti-
ated, quiescent population. Thirteen BLCs were selected by
immunohistochemistry as triple-negative ductal carcinomasBreast Cancer Research    Vol 10 No 6    Marty et al.
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(lack of ER, PR and HER2 staining) that expressed CK5/6
and/or CK14 and/or EGFR (Figure 1a). The comparison series
was composed of 11 patients with ER-negative/PR-negative
and HER2+ tumours (Figure 1a). CK5/6 was expressed in
61.5% BLCs (8 of 13) and 9.1% HER2+ (1 of 11) (Figure 1a).
Similarly, CK14 was expressed more in the same BLCs
(61.5%) than in HER2+ (9.1%) (Figure 1a). EGFR was
detected in 92.3% BLCs (12 of 13) and 36.4% HER2+ (4 of
11) (Figure 1a), in agreement with previous studies showing
EGFR expression in most BLCs and in HER2+ carcinomas
[8,44,45]. Expectedly, RPPA analysis confirmed a significantly
higher HER2 protein expression in HER2+ carcinomas com-
pared with BLCs (p = 1.6 × 10-6) (Figure 1b). Similar results
were observed by Western blotting and significantly corre-
lated with those obtained by RPPA [see Additional data file 1].
Of note, some BLCs carcinomas expressed HER2 protein but
at lower levels than those observed in HER2+ carcinomas. In
addition, these data indicated that RPPA technology could be
useful to measure in a quantitative manner the expression of
HER2 protein in human samples. Gene expression microarray
analysis confirmed that the tumours clustered according to
basal-like and HER2+ signatures [46] (Figure 1c). Therefore,
the two breast cancer populations were accurately character-
ised and the subtypes identified by immunohistochemistry cor-
responded to the gene expression classification.
Activated PI3K pathway in basal-like breast cancer
Proteomic analysis was then continued by RPPA allowing
analysis of a very limited amount of sample from biopsies
[33,37,38]. Akt was expressed at similar levels in BLCs and
HER2 carcinomas (Figure 2a) whereas the phosphorylated
and active form of Akt (S473) tended to be expressed more in
BLCs although not in a significant manner (Figure 2b). Akt
activity, defined as the phospho/total ratio, was significantly
increased in BLCs compared with HER2+ population (p =
0.026) (Figure 2c). Similar data, significantly correlated with
RPPA data, were obtained by Western blotting [see Additional
data file 2] and were in agreement with those showing an acti-
vation of Akt within a population of eight triple-negative carci-
nomas [47].
Our data further revealed that Akt was more active in BLCs
compared with HER2+ carcinomas where Akt is known to be
activated through HER2 overexpression [23-25]. We verified
by immunohistochemistry of both BLCs and HER2+ carcino-
mas that the active form of Akt was expressed in tumour cells,
with a plasma membrane localisation observed in tumours
showing strong phospho-Akt immunoreactivity [see Additional
data file 3]. We also examined the phosphorylation status of
the target of rapamycin, mTOR, particularly at the S2448 res-
idue known to be phosphorylated through PI3K/Akt signalling
pathway activation. mTOR was expressed at similar levels in
the two breast populations but was significantly more active
(phospho/total ratio) in BLCs than in HER2+ carcinomas (p =
0.015) (Figure 2d,e,f), where mTOR has been shown to be
activated [48]. The PI3K pathway was up-regulated in BLCs
compared with HER2+ as shown by the significant activation
of downstream targets such as Akt and mTOR.
Lower PTEN expression in basal-like breast cancer 
compared to HER2+ carcinomas
We then attempted to characterise the molecular mecha-
nism(s) leading to Akt activation in BLCs. We evaluated PTEN
expression because its loss has been associated with ER neg-
ative [24,49,50] and CK5/14-positive breast cancer [34].
RPPA analysis highlighted a lower expression of PTEN protein
in BLCs compared with HER2+ carcinomas in a significant
manner (p = 0.002) (Figure 3a). Similar data were obtained
when PTEN was detected by Western blotting and signifi-
cantly correlated with RPPA data [see Figures a and b in Addi-
tional data file 4]. So far, we failed to estimate PTEN level by
immunohistochemistry, possibly because of the PTEN anti-
bodies we tested and/or the AFA fixation of tissues. Lower
PTEN expression in BLCs was also detected at the mRNA
level (p = 0.0002) (Figure 3b).
In agreement with a previous report with PTEN protein levels
measured by immunohistochemistry [49], PTEN mRNA and
protein levels were well correlated (p = 0.0002) (Figure 3c)
[see Figure c in Additional data file 4], indicating that we could
estimate PTEN protein levels from transcriptomic analysis. Our
a n a l y s i s  o f  p u b l i s h e d  d a t a  [ 5 1 ]  s h o w e d  t h a t  l o w e r  P T E N
mRNA levels in BLCs compared with normal samples (p =
0.003, Mann-Whitney test, data not shown), suggesting lower
PTEN protein levels in BLCs compared with normal tissues.
We examined the expression of stathmin, which has recently
been shown to be overexpressed in low PTEN expressing
breast cancers [49]. In accordance with these published
observations, stathmin protein was overexpressed in BLCs
compared with HER2+ carcinomas (p = 0.018) (Figure 3d).
Stathmin therefore represents a potential marker for PTEN-
dependent PI3K pathway activation [49]. Altogether, tran-
scriptomic and proteomic analyses highlighted low expression
of PTEN in BLCs.
Genomic alterations at the PTEN tumour suppressor 
gene in basal-like breast cancer
We then examined whether variations in PTEN protein expres-
sion could arise from genomic alterations in our BLC popula-
tion. Genomic DNA isolated from tumours was analysed on
SNP arrays. The two populations behaved differently for PTEN
DNA copy-number (CN) in a significant manner (p = 0.005)
(Figure 4a) [see Additional data file 5]. In contrast to the entire
HER2+ population exhibiting normal PTEN CN, loss of PTEN
CN was observed in 46.1% (6 of 13) BLCs (Figure 4a) [see
Additional data file 5]. Of note is that our BLC population
included one BRCA1 tumour (c.2501delG BRCA1 mutation)
which also presented a loss of PTEN CN. We noticed that the
only double deletion of the PTEN gene was observed in a BLC
patient with a normal status of BRCA1 with the exception ofAvailable online http://breast-cancer-research.com/content/10/6/R101
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the c.4039A>G polymorphism. We also observed a gain of
PTEN CN in 2 of 13 BLCs (15.4%) (Figure 4a) [see Additional
data file 5] but these two tumours expressed PTEN protein at
a level similar to that one in BLCs with normal PTEN CN (Fig-
ure 4b).
Importantly, PTEN CN correlated with PTEN protein level in a
significant manner (p = 0.028) in the whole population (Figure
4b). These results suggest that genomic alterations at the
PTEN  locus are directly responsible for low PTEN protein
expression in about 50% of BLCs (Figure 4b). Low PTEN pro-
tein expression in the other half of BLCs may result from PTEN
promoter methylation and/or PTEN mutation. Although coding
mutations of PTEN were thought to be rare in breast cancer,
PTEN  nucleotide sequence mutations have recently been
detected exclusively in PTEN-null non-hereditary breast can-
cer [34]. However, we did not detect any PTEN mutation in
our series of 13 BLCs (data not shown), in agreement with a
recent report showing that the rare PTEN mutations observed
in breast cancer (2.3%) were restricted to hormone receptor-
positive carcinomas [33]. Therefore, low PTEN protein expres-
sion in the 50% BLCs with no PTEN CN loss may arise from
epigenetic modifications.
In addition, by analysing a public data set generated from 42
BLCs and 32 hormone receptors-positive luminal A breast
carcinomas [52], we also found a loss of PTEN CN, mainly in
BLCs, and a correlation between PTEN CN and PTEN mRNA
in the entire population (p = 3.25 × 10-7, c = 0.614, Spearman
correlation, data not shown). In conclusion, we demonstrate
the presence of genomic alterations at the PTEN locus specif-
ically in BLCs. Our findings indicate that alteration of PTEN
gene is not restricted to BRCA1-associated hereditary
tumours (mostly corresponding to a specific basal-like sub-
Figure 2
Up-regulated phosphatidylinositol 3-kinase (PI3K) signalling pathway in human basal-like breast cancers Up-regulated phosphatidylinositol 3-kinase (PI3K) signalling pathway in human basal-like breast cancers. Akt is activated in basal-like carci-
nomas (BLCs). The expression of (a) total Akt and (b) phosphorylated/active form of Akt (phospho-Akt (S473)) were measured by reverse phase 
protein array (RPPA) as well as Akt activity determined as the (c) ratio 'phospho/total' in human BLCs and human epidermal growth factor receptor 
overexpressing (HER2+) carcinomas. mTOR is activated in BLCs. Box plots show the (d) expression of mTOR and (e) its form phosphorylated via 
the PI3 kinase/Akt signalling pathway (phospho-mTOR (S2448)) determined by Western blotting as well as (f) mTOR activity (phospho/total ratio) in 
human BLCs and HER2+ carcinomas. Outliers are shown for BLCs (solid circles) and HER2+ carcinomas (open circles). The y axes represent log-
arithmic transformed relative quantifications. p values (* p < 0.05) are represented (Mann-Whitney test). Data are representative of four and two sep-
arate experiments for RPPA and Western-blot, respectively.Breast Cancer Research    Vol 10 No 6    Marty et al.
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group) as recently suggested [34], but could be extended to
the entire BLC population. These genetic modifications may
drive to an aberrant PTEN-dependent signalling pathway in the
whole BLC population.
PTEN-dependent activation of Akt in basal-like breast 
cancer
Low PTEN expression may therefore be responsible for Akt
activation in BLCs. Indeed, data obtained by RPPA demon-
strated that Akt activity correlated negatively with PTEN
expression levels in BLCs (p = 0.036) (Figure 5) but not in
HER2+ carcinomas (not shown). Similar conclusions arose
from Western blot analysis [see Figure d in Additional data file
4]. Altogether, our data demonstrated a PTEN-dependent acti-
vation of Akt in BLCs, consistent with recent work showing
higher phospho-Akt levels in PTEN-low compared with PTEN-
high breast cancers [33].
We can not rule out the hypothesis that Akt could be activated
through multiple mechanisms in BLCs, and not only through
low PTEN expression. For example, transcriptomic microarray
analysis revealed that the type II inositol polyphosphate-4-
phosphatase mRNAs were expressed at significantly lower
levels in BLCs compared with HER2+ human tumours
(INPP4B reporter 205376_at from Affymetrix; p = 0.0001,
data not shown). As INPP4B has been shown to negatively
regulate Akt activity [53], its lower expression may represent
an alternative pathway for Akt activation in BLCs. However, we
could not test this hypothesis at a proteomic level because of
the poor quality of the INPP4B antibody available. Mutations of
PIK3CA, although more frequent in hormone receptor-positive
tumours (34.5%) and HER2+ carcinomas (22.7%) occurs in
BLCs (8.3%) and could represent another way to activate the
PI3K signalling pathway in these tumours [33].
Figure 3
Lower phosphatase and tensin homolog deleted on chromosome 10 (PTEN) expression in human basal-like cancers (BLCs) compared with human  epidermal growth factor receptor overexpressing (HER2+) carcinomas Lower phosphatase and tensin homolog deleted on chromosome 10 (PTEN) expression in human basal-like cancers (BLCs) compared 
with human epidermal growth factor receptor overexpressing (HER2+) carcinomas. (a) Lower PTEN protein levels in BLCs compared with 
HER2+ carcinomas. PTEN protein level was quantified by reverse phase protein array (RPPA). Outliers are shown for BLCs (solid circles) and 
HER2+ carcinomas (open circles). Data are representative of four separate experiments. (b) Lower mRNA PTEN level (probeset 225363_at) in 
BLCs compared with HER2+ carcinomas. An outlier is present in BLC population (solid circles). (c) Correlation between PTEN protein measured by 
RPPA and PTEN messenger in the entire tumour population. Linear regression, Spearman correlation c and p value are presented. BLCs (solid cir-
cles) and HER2+ carcinomas (open circles) are shown. (d) Stathmin is overexpressed in BLCs compared with HER2+ carcinomas. Box plots indi-
cate the levels of stathmin protein measured by RPPA within the two populations. Data are representative of four separate experiments. P values are 
shown (a,b,d: Mann-Whitney test). * p < 0.05, ** p < 0.01, *** p < 0.001. Protein and mRNA relative quantifications were logarithmic transformed.Available online http://breast-cancer-research.com/content/10/6/R101
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Figure 4
Loss of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) DNA copy-number (CN) in human basal-like breast cancers Loss of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) DNA copy-number (CN) in human basal-like breast cancers. 
(a) Basal-like carcinomas (BLCs) and human epidermal growth factor receptor overexpressing (HER2+) carcinomas behaved differently for PTEN 
CN in a significant manner. Recurrent DNA CN alterations were observed around the PTEN gene (between 72,260,000 and 93,93,000 bp of chro-
mosome 10) in BLCs compared with HER2+ carcinomas. Frequencies of genome CN gain (red) and loss (green) were calculated using the FrAGL 
(Frequency of Amplicon, Gain and Loss) option of VAMP software (Visualisation and Analysis of array-CGH, transcriptome and other Molecular Pro-
files) [63]. The vertical blue bar represents PTEN position from 89,613,175 to 89,718,511 bp. Percentages of tumours with loss, normal or gain of 
PTEN CN are presented within the two populations in the table. p value is shown (** p < 0.01, fisher exact test). (b) Correlation between PTEN pro-
tein level and PTEN DNA CN. PTEN protein level was quantified as in Figure 3a. Linear regression, Spearman correlation c and p value (* p < 0.05) 
are presented. BLCs (solid circles) and HER2+ carcinomas (open circles) are shown. The two vertical black lines (X = 2 ± 0.28) separate loss/nor-
mal/gain PTEN CN (forceGL parameter: 0.28).Breast Cancer Research    Vol 10 No 6    Marty et al.
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PI3K but not mTOR inhibition induces apoptosis in 
basal-like cell lines
Akt activity was examined by Western blotting in four human
basal-like cell lines (BT20, HCC38, HCC1937 and MDA-MB-
468), one HER2+ (SKBr3) and one luminal (MDA-MB-453)
human breast cell lines as well as in an epidermoid carcinoma
cell line (A431) for a control (Figure 6a). Akt was phosphor-
ylated indicating that PI3K pathway was activated in all breast
cell lines analyzed (Figure 6a). PTEN was weakly expressed
(BT20) or not detectable specifically in basal-like cell lines
(Figure 6a). We noticed highest levels of Akt phosphorylation
in MDA-MB-453 and BT20 (Figure 6a), and this may result
from the mutation of the PI3K catalytic subunit (PIK3CA)
reported in these two cell lines [24,33]. PTEN  has been
shown to be mutated in MDA-MB-468 [33]. Therefore, similar
results were obtained from human biopsies and cell lines
revealing an activation of Akt associated with a low/lack
expression of PTEN in the basal-like population.
We then investigated whether the inhibition of the PI3K path-
way altered proliferation and apoptosis of basal-like cell lines.
First, we examined the growth inhibition response of three
basal-like cell lines (BT20, HCC1937 and MDA-MB-468)
treated with the PI3K inhibitor LY294002 or the mTOR inhibi-
tor rapamycin. Exposure to LY294002 induced an inhibition of
the proliferation for all three cell lines with a lower IC50 for
MDA-MB-468 (IC50  = 7.6 ± 1.4 μM) compared with
HCC1937 (IC50 = 14.5 ± 3.8 μM) and BT20 (IC50 = 13.3 ±
2.8 μM) (Figure 6b). The IC50 were in the same range than
those obtained previously for MDA-MB-468 (IC50 = 9.5 μM)
[54] and for other breast cell lines (2 to 20 μM LY294002)
[55]. MDA-MB-468 cells were the most sensitive cells to
LY294002 in agreement with the idea that PTEN mutation
render cells more sensitive to growth inhibition by that inhibitor
[33]. Exposure to rapamycin led to a growth inhibition that was
not complete. The IC50 for rapamycin were not reached for
HCC1937 and BT20 cell lines. MDA-MB-468 cells were the
most sensitive cells to rapamycin with an IC50 = 1.2 ± 0.5 nM
(Figure 6b). Similar data have been published previously for
MDA-MB-468 cells (IC50 = 1 nM) [56,57].
We next evaluated whether the growth inhibition resulted from
apoptosis. Basal-like cell lines were treated with concentra-
tions of inhibitors used to induce apoptosis, that is 50 to 100
μM LY294002 or 100 nM rapamycin [55-57]. Apoptosis was
analysed 24 hours later by measuring casapase 3/7 activity
(Figure 6c) and PARP cleavage (Figure 6d). In contrast to
rapamycin, LY294002 treatment-induced apoptosis in all
basal-like cell lines as judged by a rapamycin dose-dependent
increased of caspase 3/7 activity (Figure 6c) and PARP cleav-
age (Figure 6d). These data are in agreement with a recent
paper showing that LY294002 treatment, but not rapamycin,
induced apoptosis in other breast cell lines [55]. It is likely that
rapamycin inhibited basal-like cell proliferation by arresting the
cell cycle in the G1 phase as reported for other breast cell
lines [56].
In conclusion, exposure of basal-like cell lines to PI3K or
mTOR inhibitors led to cell growth arrest but apoptosis was
only observed in cells treated with LY294002. The inhibition
of PI3K will directly affect Akt activity, which is involved in cell
death and survival through several targets such as Bad,
whereas the inhibition of mTOR, which acts downstream of
Akt, is expected to inhibit proliferation but not apoptosis [28].
Moreover, the inhibition of mTOR may contribute to an unex-
pected activation of Akt through a negative feedback loop
[58,59]. In order to bypass feedback loops, it may be more effi-
cient to target PI3K or Akt than inhibiting mTOR. In contrast to
LY294002, which broadly acts on the majority of PI3Ks and
other related kinases [60], inhibitors of specific PI3K isoforms
were recently identified [61]. In breast cell lines, PTEN loss
was shown to sensitise to p110 beta inhibitors, a ubiquitously
expressed class IA PI3K isoform [61]. Moreover, the inhibition
of p110 beta was shown to block the tumourigenesis caused
by  PTEN  loss in prostate [62]. Although further work is
needed, these observations suggest that p110 beta may rep-
resent an attractive target for the treatment of patients with low
PTEN expressing carcinomas such as BLCs.
Conclusion
Significant differences of protein expression patterns were
observed between BLCs and HER2+ carcinomas, two types
of highly proliferative breast cancers. Our data demonstrate
that: the PI3K pathway is activated in BLCs and, to a higher
extent than in HER2+ carcinomas, is known to have up-regu-
lated Akt and mTOR activities; BLCs express less PTEN com-
pared with HER2+ carcinomas and normal tissues; genomic
Figure 5
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN)- dependent activation of Akt in human basal-like breast cancers Phosphatase and tensin homolog deleted on chromosome 10 
(PTEN)-dependent activation of Akt in human basal-like breast 
cancers. PTEN protein levels are correlated negatively with Akt activity 
in human basal-like cancer (BLC). Akt activity and PTEN protein levels 
were measured as in Figures 2c and 3a, respectively. BLCs (solid cir-
cles), linear regression, Spearman correlation c and p value (* p < 0.05) 
are shown.Available online http://breast-cancer-research.com/content/10/6/R101
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alterations at the PTEN locus are specifically found in BLCs;
low PTEN expression in BLCs is associated with lost of PTEN
DNA CN; Akt activity is dependent of PTEN expression in
BLCs; similarly to human biopsies, basal-like breast cell lines
exhibit low PTEN expression and activated Akt; PI3K or mTOR
inhibition induced growth arrest in basal-like cell lines; PI3K
inhibition, but not mTOR inhibition, induced apoptosis of
basal-like cell lines; and finally that RPPA is a powerful quanti-
tative tool for proteomic analysis and to examine signalling
pathways in human tumours. Our study provides insight into
the molecular pathology of BLCs with therapeutic implications
and encourages the targeting of key players within the PI3K
pathway, such as specific PI3K/Akt isoforms for the manage-
ment of patients with poor prognosis BLC.
Figure 6
Phosphatidylinositol 3-kinase (PI3K) and mTOR inhibitors inhibit basal-like cell line proliferation whereas apoptosis is induced only by PI3K inhibition Phosphatidylinositol 3-kinase (PI3K) and mTOR inhibitors inhibit basal-like cell line proliferation whereas apoptosis is induced only by 
PI3K inhibition. (a) Akt activation is associated with low/lack of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) expression in 
human basal-like cell lines. The expression of Akt, phospho-Akt (S473) and PTEN were analysed by Western blotting in four basal-like (BT20, 
HCC38, HCC1937 and MDA-MB-468), one human epidermal growth factor receptor overexpressing (HER2+) (SKBr3) and one luminal (MDA-MB-
453) human breast cell lines as well as in epidermal growth factor stimulated (EGF) or not (-) A431 cells. (b) PI3K and mTOR inhibition induce cell 
growth arrest of basal-like cell lines. BT20 (blue triangle), HCC1937 (red square) and MDA-MB-468 (green diamond) cells were exposed continu-
ously for seven days to increasing concentrations of LY294002 (upper panel) or rapamycin (lower panel). Growth was assessed by 3-(4,5-dimethyl-
thiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) dye conversion and presented as the percentage of control cell growth inhibition obtained from 
DMSO-treated cells. The x axes represent logarithmic transformed concentration of drugs. (c,d) The inhibition of PI3K, but not mTOR, induces apop-
tosis in basal-like cell lines. BT20, HCC1937 and MDA-MB-468 were exposed to varying concentrations of LY294002 (0 to 100 μM) or rapamycin 
(0 to 100 nM) for 24 hours and apoptosis was detected by measuring (c) caspase3/7 activity and the (d) cleavage of PARP (cPARP). (c) Caspase 
3/7 activity was normalised by caspase 3/7 activity from vehicle-treated cells. (d) Actin was used as a loading control. The data represented the (b,c) 
average of three separate experiments performed in triplicates or are representative of (a,d) three separate experiments. Error bars represent stand-
ard deviation and p values (** p < 0.01, *** p < 0.001) were calculated by using Student's t test.Breast Cancer Research    Vol 10 No 6    Marty et al.
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The following Additional files are available online:
Additional file 1
A PDF containing figures showing the expression of 
HER2 measured by Western blotting and its correlation 
with RPPA data. Figure a illustrates the expression of 
total HER2 protein expression measured by Western 
blotting in human BLCs and HER2+ carcinomas. P value 
(*** p < 0.001) is represented (Mann-Whitney test). 
Figure b illustrates the correlation between RPPA and 
Western-blotting analysis for HER2 protein expression. 
Protein expressions are logarithmic transformed and 
illustrated by box plots with p values (Mann-Whitney 
test). Outliers are shown within the BLCs (solid circles) 
and HER2+ carcinomas (open circles) populations. The 
correlations are estimated using the Spearman 
correlation test (c) from logarithmic transformed values. 
Linear regression and p values are indicated. BLCs (solid 
circles) and HER2+ carcinomas (open circles) are 
shown. The significant p values are represented by stars 
(* p < 0.05, ** p < 0.01, *** p < 0.001).
See http://www.biomedcentral.com/content/
supplementary/bcr2204-S1.pdf
Additional file 2
A PDF containing figures showing Akt activation in basal-
like breast cancer measured by Western blotting and its 
correlation with RPPA data. Figures a, b and c illustrate 
the expression of total Akt, the phosphorylated/active 
form of Akt (phospho-Akt (S473)), and the activity of Akt 
determined as the 'phospho/total' ratio, respectively, in 
human BLCs and HER2+ carcinomas. Figures d and e 
show the correlation between RPPA and Western 
blotting data for Akt and phospho-Akt protein 
expressions, respectively. Protein expressions are 
logarithmic transformed and illustrated by box plots with 
p values (Mann-Whitney test). Outliers are shown within 
the BLCs (solid circles) and HER2+ carcinomas (open 
circles) populations. The correlations are estimated 
using the Spearman correlation test (c) from logarithmic 
transformed values. Linear regression and p values are 
indicated. BLCs (solid circles) and HER2+ carcinomas 
(open circles) are shown. The significant p values are 
represented by stars (* p < 0.05, ** p < 0.01, *** p < 
0.001).
See http://www.biomedcentral.com/content/
supplementary/bcr2204-S2.pdf
Additional file 3
A PDF containing a figure showing that the active form of 
Akt is detected in tumour cells within the biopsies by 
immunohistochemistry. Expression and localisation of 
phospho-Akt (S473), and hence activated Akt, was 
analysed on TMA in BLCs and HER2+ carcinomas. 
Phospho-Akt showed low, medium and high expression 
depending on the tumour samples. Phospho-Akt is 
preferentially expressed in tumour cells. It is located in 
the cytoplasm and at the plasma membrane particularly 
in tumour cells with strong staining. All 
photomicrographs are of the same 40× magnification 
(scale bar, 20 μm).
See http://www.biomedcentral.com/content/
supplementary/bcr2204-S3.pdfAvailable online http://breast-cancer-research.com/content/10/6/R101
Page 13 of 15
(page number not for citation purposes)
Acknowledgements
This work was supported by Institut de Recherches Servier and Institut 
Curie. GR was supported by a grant of Institut National du Cancer 
(INCa). We thank Paul Delgado, Sophie Duminil, Michèle Galut and 
Blandine Massemin for the purification of DNA and RNA from biopsies 
(Service de Pathologie, Institut Curie), Cécile Reyes, Audrey Rapinat, 
Benoit Albaud, David Gentien, Jean-Claude Haw-king-chon, Dr Charles 
Decraene and Dr Jean-Philippe Meyniel for genome and transcriptome 
microarrays (Département de Transfert, Institut Curie), Aurélie Cédenot 
for immunohistochemistry staining (Service de Pathologie, Institut 
Curie), Patricia Legoix-Né (Plateforme de Génomique, Institut Curie) 
and Elodie Manié (INSERM U830, Institut Curie) for advice regarding 
PTEN sequencing, and Yann de Rycke for statistical advice (Départe-
ment de Biostatistiques, Institut Curie). We are indebted to Dr Sergio 
Roman-Roman (Département de Transfert, Institut Curie), Professor 
Dominique Stoppa-Lyonnet (INSERM U830, Service de Pathologie, 
Institut Curie) and Dr Xavier Sastre (Service de Pathologie, Institut 
Curie). We thank Séverine Lair (INSERM U900, Institut Curie) for load-
ing the transcriptomic data into the Curie Institute microarray dataset 
repository. Finally, we are grateful Dr Minzi Ruan and Min Ma for their 
help for RPPA quantification (VigeneTech, Inc).
References
1. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A,
Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification
and prognosis based on gene expression profiles from a pop-
ulation-based study.  Proc Natl Acad Sci USA 2003,
100:10393-10398.
2. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng
S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning
PE, Brown PO, Borresen-Dale AL, Botstein D: Repeated obser-
vation of breast tumor subtypes in independent gene expres-
sion data sets.  Proc Natl Acad Sci USA 2003, 100:8418-8423.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H,
Hastie T, Eisen MB, Rijn M van de, Jeffrey SS, Thorsen T, Quist H,
Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-
Dale AL: Gene expression patterns of breast carcinomas dis-
tinguish tumor subclasses with clinical implications.  Proc Natl
Acad Sci USA 2001, 98:10869-10874.
4. Perou CM, Sorlie T, Eisen MB, Rijn M van de, Jeffrey SS, Rees CA,
Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamen-
schikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL,
Brown PO, Botstein D: Molecular portraits of human breast
tumours.  Nature 2000, 406:747-752.
5. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF,
Bild A, Iversen ES, Liao M, Chen CM, West M, Nevins JR, Huang
AT: Gene expression predictors of breast cancer outcomes.
Lancet 2003, 361:1590-1596.
6. van 't Veer LJ, Dai H, Vijver MJ van de, He YD, Hart AA, Mao M,
Peterse HL, Kooy K van der, Marton MJ, Witteveen AT, Schreiber
GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH:
Gene expression profiling predicts clinical outcome of breast
cancer.  Nature 2002, 415:530-536.
7. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M,
Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan
C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L: Breast cancer
molecular subtypes respond differently to preoperative chem-
otherapy.  Clin Cancer Res 2005, 11:5678-5685.
8. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hern-
andez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA,
Ragaz J, Gown AM, Gilks CB, Rijn M van de, Perou CM: Immuno-
histochemical and clinical characterization of the basal-like
subtype of invasive breast carcinoma.  Clin Cancer Res 2004,
10:5367-5374.
9. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo
WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Toku-
yasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A,
Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW:
Genomic and transcriptional aberrations linked to breast can-
cer pathophysiologies.  Cancer Cell 2006, 10:529-541.
10. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-
Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Gold-
stein DR, Piccart M, Delorenzi M: Meta-analysis of gene-expres-
sion profiles in breast cancer: toward a unified understanding
of breast cancer sub-typing and prognosis signatures.  Breast
Cancer Res 2008, 10:R65.
11. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F,
Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T,
Berns EM, Atkins D, Foekens JA: Gene-expression profiles to
predict distant metastasis of lymph-node-negative primary
breast cancer.  Lancet 2005, 365:671-679.
12. Reis-Filho JS, Tutt AN: Triple negative tumours: a critical review.
Histopathology 2008, 52:108-118.
Additional file 4
A PDF containing a figure that validates the PTEN-
dependent activation of Akt observed by RPPA in basal-
like cancer with Western blot technology. Figure a 
shows PTEN protein level. Data are representative of two 
separate experiments. Figure b indicates the correlation 
between RPPA and Western blotting analysis for PTEN 
protein expression. Figure c exhibits the correlation 
between PTEN protein measured by Western blotting 
and PTEN messenger (probeset 225363_at). Figure d 
shows that PTEN protein levels correlates negatively 
with Akt activity within the BLC population (solid circles). 
Akt activity and PTEN protein levels were measured by 
Western blotting as in Figure a to c in Additional file 2 
and as in Figure a in Additional file 4, respectively. 
Protein expressions are logarithmic transformed and 
illustrated by box plots with p values (Mann-Whitney 
test). Outliers are shown within the BLCs (solid circles) 
and HER2+ carcinomas (open circles) populations. The 
correlations are estimated using the Spearman 
correlation test (c) from logarithmic transformed values. 
Linear regression and p values are indicated. BLCs (solid 
circles) and HER2+ carcinomas (open circles) are 
shown. The significant p values are represented by stars 
(* p < 0.05, ** p < 0.01, *** p < 0.001).
See http://www.biomedcentral.com/content/
supplementary/bcr2204-S4.pdf
Additional file 5
A PDF containing a figure that illustrates recurrent 
genomic alterations around PTEN locus in human basal-
like breast cancers. Genomic analysis using the VAMP 
software (Visualization and Analysis of array-CGH, 
transcriptome and other Molecular Profiles) [60] around 
the PTEN gene (between 80,676,000 and 98,604,000 
bp of chromosome 10) are shown for all the 13 BLCs 
(upper panel) and the 11 HER2+ tumours (lower panel). 
Each row represents one tumour profile. Gains are in red, 
losses in green and absence of alterations in yellow. The 
vertical blue bars represent the position of PTEN from 
89,613,175 to 89,718,511 bp.
See http://www.biomedcentral.com/content/
supplementary/bcr2204-S5.pdfBreast Cancer Research    Vol 10 No 6    Marty et al.
Page 14 of 15
(page number not for citation purposes)
13. Fadare O, Tavassoli FA: Clinical and pathologic aspects of
basal-like breast cancers.  Nat Clin Pract Oncol 2008,
5:149-159.
14. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens
JA, Martens JW: Subtypes of breast cancer show preferential
site of relapse.  Cancer Res 2008, 68:3108-3114.
15. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H,
Bartelink H, Vijver MJ van de: Gene expression profiling and his-
topathological characterization of triple-negative/basal-like
breast carcinomas.  Breast Cancer Res 2007, 9:R65.
16. Couzin J: Cancer research. Probing the roots of race and can-
cer.  Science 2007, 315:592-594.
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A,
Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron
D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M,
Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohr-
isch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C,
Straehle C, McFadden E, et al.:  Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer.  N Engl J Med
2005, 353:1659-1672.
18. Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: a crit-
ical review.  J Clin Oncol 2008, 26:2568-2581.
19. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL: Decon-
structing the molecular portrait of basal-like breast cancer.
Trends Mol Med 2006, 12:537-544.
20. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale
R, Sigal-Zafrani B, Longy M, Raynal V, Pierron G, de Mascarel I,
Taris C, Stoppa-Lyonnet D, Pierga JY, Salmon R, Sastre-Garau X,
Fourquet A, Delattre O, de Cremoux P, Aurias A: Identification of
typical medullary breast carcinoma as a genomic sub-group of
basal-like carcinomas, a heterogeneous new molecular entity.
Breast Cancer Res 2007, 9:R24.
21. Cleator S, Heller W, Coombes RC: Triple-negative breast can-
cer: therapeutic options.  Lancet Oncol 2007, 8:235-244.
22. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y,
Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, Palacios J:
Sox2: a possible driver of the basal-like phenotype in sporadic
breast cancer.  Mod Pathol 2007, 20:474-481.
23. Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S,
Morita M, Kakeji Y, Baba H, Maehara Y: Activation of PI3K/Akt
signaling and hormone resistance in breast cancer.  Breast
Cancer 2006, 13:137-144.
24. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malm-
strom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Par-
sons R: PIK3CA mutations correlate with hormone receptors,
node metastasis, and ERBB2, and are mutually exclusive with
PTEN loss in human breast carcinoma.  Cancer Res 2005,
65:2554-2559.
25. Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K,
Koga T, Morita M, Kakeji Y, Maehara Y: Coexistence of the loss
of heterozygosity at the PTEN locus and HER2 overexpression
enhances the Akt activity thus leading to a negative progester-
one receptor expression in breast carcinoma.  Breast Cancer
Res Treat 2007, 101:249-257.
26. Shaw RJ, Cantley LC: Ras, PI(3)K and mTOR signalling controls
tumour cell growth.  Nature 2006, 441:424-430.
27. Engelman JA, Luo J, Cantley LC: The evolution of phosphatidyli-
nositol 3-kinases as regulators of growth and metabolism.
Nat Rev Genet 2006, 7:606-619.
28. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the
PI3K/AKT pathway for cancer drug discovery.  Nat Rev Drug
Discov 2005, 4:988-1004.
29. Liu W, Bagaitkar J, Watabe K: Roles of AKT signal in breast can-
cer.  Front Biosci 2007, 12:4011-4019.
30. Dillon RL, White DE, Muller WJ: The phosphatidyl inositol 3-
kinase signaling network: implications for human breast can-
cer.  Oncogene 2007, 26:1338-1345.
31. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins
CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M,
Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J,
Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL,
Thomas JE: A transforming mutation in the pleckstrin homol-
ogy domain of AKT1 in cancer.  Nature 2007, 448:439-444.
32. Kim MS, Jeong EG, Yoo NJ, Lee SH: Mutational analysis of
oncogenic AKT E17K mutation in common solid cancers and
acute leukaemias.  Br J Cancer 2008, 98:1533-1535.
33. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL,
Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai
L, Nolden LK, Horlings H, Berns K, Hung MC, Vijver MJ van de,
Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT: An inte-
grative genomic and proteomic analysis of PIK3CA, PTEN, and
AKT mutations in breast cancer.  Cancer Res 2008,
68:6084-6091.
34. Saal LH, Gruvberger-Saal SK, Persson C, Lovgren K, Jumppanen
M, Staaf J, Jonsson G, Pires MM, Maurer M, Holm K, Koujak S,
Subramaniyam S, Vallon-Christersson J, Olsson H, Su T, Memeo
L, Ludwig T, Ethier SP, Krogh M, Szabolcs M, Murty VV, Isola J,
Hibshoosh H, Parsons R, Borg A: Recurrent gross mutations of
the PTEN tumor suppressor gene in breast cancers with defi-
cient DSB repair.  Nat Genet 2008, 40:102-107.
35. Azoulay S, Lae M, Freneaux P, Merle S, Al Ghuzlan A, Chnecker C,
Rosty C, Klijanienko J, Sigal-Zafrani B, Salmon R, Fourquet A, Sas-
tre-Garau X, Vincent-Salomon A: KIT is highly expressed in ade-
noid cystic carcinoma of the breast, a basal-like carcinoma
associated with a favorable outcome.  Mod Pathol 2005,
18:1623-1631.
36. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC,
Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A,
McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A,
Sturgeon C, Taube SE, Tubbs R, Vance GH, Vijver M van de,
Wheeler TM, Hayes DF: American Society of Clinical Oncology/
College of American Pathologists guideline recommendations
for human epidermal growth factor receptor 2 testing in breast
cancer.  J Clin Oncol 2007, 25:118-145.
37. Gulmann C, Sheehan KM, Kay EW, Liotta LA, Petricoin EF 3rd:
Array-based proteomics: mapping of protein circuitries for
diagnostics, prognostics, and therapy guidance in cancer.  J
Pathol 2006, 208:595-606.
38. Chan SM, Ermann J, Su L, Fathman CG, Utz PJ: Protein microar-
rays for multiplex analysis of signal transduction pathways.
Nat Med 2004, 10:1390-1396.
39. Rigaill G, Hupe P, Almeida A, La Rosa P, Meyniel JP, Decraene C,
Barillot E: ITALICS: an algorithm for normalization and DNA
copy number calling for Affymetrix SNP arrays.  Bioinformatics
2008, 24:768-774.
40. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E: Analysis of
array CGH data: from signal ratio to gain and loss of DNA
regions.  Bioinformatics 2004, 20:3413-3422.
41. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F: A
Model-Based Background Adjustment for Oligonucleotide
Expression Arrays.  J Am Stat Assoc 2004, 99:909-917.
42. The Curie Institute microarray dataset repository   [ h t t p : / /
microarrays.curie.fr/publications/transfert_signalisation/
breast_transcriptome_P1/]
43. The R Project for Statistical Computing   [http://www.r-
project.org]
44. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S,
Tse CK, Nyante S, Millikan RC: Identification of a basal-like sub-
type of breast ductal carcinoma in situ.  Hum Pathol 2007,
38:197-204.
45. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore
DT, Perou CM: Phenotypic evaluation of the basal-like subtype
of invasive breast carcinoma.  Mod Pathol 2006, 19:264-271.
46. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey
LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer
LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D,
Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M,
Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, et al.: The
molecular portraits of breast tumors are conserved across
microarray platforms.  BMC Genomics 2006, 7:96.
47. Umemura S, Yoshida S, Ohta Y, Naito K, Osamura RY, Tokuda Y:
Increased phosphorylation of Akt in triple-negative breast can-
cers.  Cancer Sci 2007, 98:1889-1892.
48. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y,
Yang W, Smith TL, Shi D, Yu D: Activation of the Akt/mamma-
lian target of rapamycin/4E-BP1 pathway by ErbB2 overex-
pression predicts tumor progression in breast cancers.  Clin
Cancer Res 2004, 10:6779-6788.
49. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB,
Maurer M, Koujak S, Ferrando AA, Malmstrom P, Memeo L, Isola J,
Bendahl PO, Rosen N, Hibshoosh H, Ringner M, Borg A, Parsons
R:  Poor prognosis in carcinoma is associated with a gene
expression signature of aberrant PTEN tumor suppressorAvailable online http://breast-cancer-research.com/content/10/6/R101
Page 15 of 15
(page number not for citation purposes)
pathway activity.  Proc Natl Acad Sci USA 2007,
104:7564-7569.
50. Depowski PL, Rosenthal SI, Ross JS: Loss of expression of the
PTEN gene protein product is associated with poor outcome
in breast cancer.  Mod Pathol 2001, 14:672-676.
51. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A,
Liao X, Iglehart JD, Livingston DM, Ganesan S: X chromosomal
abnormalities in basal-like human breast cancer.  Cancer Cell
2006, 9:121-132.
52. Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircou-
lomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Sch-
oenmakers E, Viens P, Jacquemier J, Birnbaum D, Bertucci F,
Chaffanet M: Integrated profiling of basal and luminal breast
cancers.  Cancer Res 2007, 67:11565-11575.
53. Barnache S, Le Scolan E, Kosmider O, Denis N, Moreau-Gachelin
F: Phosphatidylinositol 4-phosphatase type II is an erythropoi-
etin-responsive gene.  Oncogene 2006, 25:1420-1423.
54. DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB,
Hidalgo M: Reduced PTEN expression in breast cancer cells
confers susceptibility to inhibitors of the PI3 kinase/Akt path-
way.  Ann Oncol 2004, 15:1510-1516.
55. Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefstrom J,
Hautaniemi S, Monni O: Deciphering downstream gene targets
of PI3K/mTOR/p70S6K pathway in breast cancer.  BMC
Genomics 2008, 9:348.
56. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills
GB, Hung MC, Meric-Bernstam F: Determinants of rapamycin
sensitivity in breast cancer cells.  Clin Cancer Res 2004,
10:1013-1023.
57. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB,
Meric-Bernstam F: Targeting mammalian target of rapamycin
synergistically enhances chemotherapy-induced cytotoxicity
in breast cancer cells.  Clin Cancer Res 2004, 10:7031-7042.
58. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ: Rapamycin
induces feedback activation of Akt signaling through an IGF-
1R-dependent mechanism.  Oncogene 2007, 26:1932-1940.
59. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H,
Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N: mTOR
inhibition induces upstream receptor tyrosine kinase signaling
and activates Akt.  Cancer Res 2006, 66:1500-1508.
60. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N,
Timms JF, Waterfield MD: Exploring the specificity of the PI3K
family inhibitor LY294002.  Biochem J 2007, 404:15-21.
61. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss
W, Shokat KM, Stokoe D: A chemical screen in diverse breast
cancer cell lines reveals genetic enhancers and suppressors
of sensitivity to PI3K isotype-selective inhibition.  Biochem J
2008, 415:97-110.
62. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti
S, Loda M, Roberts TM, Zhao JJ: Essential roles of PI(3)K-
p110beta in cell growth, metabolism and tumorigenesis.
Nature 2008, 454:776-779.
63. La Rosa P, Viara E, Hupe P, Pierron G, Liva S, Neuvial P, Brito I,
Lair S, Servant N, Robine N, Manie E, Brennetot C, Janoueix-Lero-
sey I, Raynal V, Gruel N, Rouveirol C, Stransky N, Stern MH, Delat-
tre O, Aurias A, Radvanyi F, Barillot E: VAMP: visualization and
analysis of array-CGH, transcriptome and other molecular pro-
files.  Bioinformatics 2006, 22:2066-2073.